附件 1 ：全文
请输入关键词
历史搜索
热门搜索
- GLP-1
ich guideline m13a on bioequivalence for immediate-release solid oral dosage forms - scientific guideline(ich m13a指南，速释固体口服剂型的生物等效性-科学指南)
发布日期
2024-08-22
发文字号
/
信息分类
指导原则
有效地区
/
时效性
尚未生效
实施日期
2024-01-25
颁发部门
欧洲药品管理局（EMA）
正文内容
<END>
最新政策法规资讯
-
摩熵医药2024-12-17
-
Pharma CMC2024-10-15
-
摩熵医药（原药融云）2024-08-21
-
数屿医械2024-06-24
-
数屿医械2024-06-13
-
数屿医械2024-05-30
-
摩熵医药（原药融云）2024-05-27
-
药事纵横2024-02-28
-
药通社2023-12-26
-
摩熵医药（原药融云）2023-12-13
对摩熵医药数据库感兴趣，可以免费体验产品
最新指导原则
-
国家药监局药审中心关于发布<濒危动物类中药材人工制成品研究技术指导原则(试行)>和<替代或者减去已上市中药处方中濒危药味研究技术指导原则(试行)>的通告(2024年第50号)
2024-12-11
-
关于公开征求ich<m15:模型引导的药物研发一般原则>指导原则草案意见的通知
2024-12-06
-
guideline on core smpc for human normal immunoglobulin for subcutaneous and intramuscular administration (scig/imig)(人用皮下及肌内注射正常免疫球蛋白(scig/imig)核心摘要产品特性指南)
2024-12-05
-
draft guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (scig/imig) - revision 2(人正常免疫球蛋白皮下和/或肌内给药(scig/imig)临床研究指南草案-第二版)
2024-12-05
-
Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics
2024-11-15
-
Guidance for Industry: FDA's Voluntary Qualified Importer Program
2024-11-14
-
CPG Sec 540.525 Scombrotoxin (Histamine)-forming Fish and Fishery Products – Decomposition and Histamine (CPG 7108.24)
2024-11-01
-
cpg sec 540.525 scombrotoxin (histamine)-forming fish and fishery products – decomposition and histamine (cpg 7108.24)(cpg 第540.525节:产生组胺的鱼类和水产品——分解和组胺(cpg 7108.24))
2024-11-01
-
Study Data Technical Conformance Guide - Technical Specifications Document
2024-10-31
-
guideline on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease of the lower extremities(下肢外周动脉阻塞性疾病治疗药物临床试验指导原则)
2024-10-31
-
study data technical conformance guide - technical specifications document(研究数据技术合规指南——技术规格文档)
2024-10-31
-
Amoxicillin;Clarithromycin;Vonoprazan Fumarate(阿莫西林;克拉霉素;富马酸伏诺拉生-BE指导原则)
2024-10-30
-
Urban health capacities: assessment and response action guide
2024-10-30
-
M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms
2024-10-30
-
m13a bioequivalence for immediate-release solid oral dosage forms(m13a 即释型固体口服制剂的生物等效性)
2024-10-30
同部门最新指导原则
-
guideline on core smpc for human normal immunoglobulin for subcutaneous and intramuscular administration (scig/imig)(人用皮下及肌内注射正常免疫球蛋白(scig/imig)核心摘要产品特性指南)
2024-12-05
-
draft guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (scig/imig) - revision 2(人正常免疫球蛋白皮下和/或肌内给药(scig/imig)临床研究指南草案-第二版)
2024-12-05
-
guideline on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease of the lower extremities(下肢外周动脉阻塞性疾病治疗药物临床试验指导原则)
2024-10-31
-
concept paper on clinical evaluation of therapeutic radiopharmaceuticals in oncology(肿瘤学中治疗性放射药物临床评估的概念论文)
2024-10-11
-
overview of comments received on 'draft guideline on quality and equivalence of topical products' (ema/chmp/qwp/708282/2018)(关于“外用制剂质量和等效性指南草案”(ema/chmp/qwp/708282/2018)的意见概述)
2024-10-01
-
guideline on quality and equivalence of locally applied, locally acting cutaneous products(关于局部应用、局部作用皮肤产品的质量和等效性指南)
2024-10-01
-
reflection paper on establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation application(关于在上市许可申请中作为关键证据提交的单臂试验建立疗效的反思文件)
2024-09-16
-
overview of comments received on the ’guideline on the environmental risk assessment of medicinal products for human use’ (emea/chmp/swp/4447/00 rev. 1)(关于<人用药品环境风险评估指南>(emea/chmp/swp/4447/00 rev. 1)所收到意见的概述)
2024-09-11
-
draft guideline on clinical development of medicinal products for the treatment and prevention of bipolar disorder - revision 1(治疗和预防双相情感障碍药品临床开发指南草案 - 第1版)
2024-09-09
-
ich guideline m13a on bioequivalence for immediate-release solid oral dosage forms - scientific guideline(ich m13a指南，速释固体口服剂型的生物等效性-科学指南)
2024-08-22
-
product-specific bioequivalence guidance(特定产品的生物等效性指导原则)
2024-07-26
-
paliperidone palmitate depot suspension for injection (every 3 months) 175, 263, 350 and 525 mg product-specific bioequivalence guidance(棕榈酸帕利哌酮注射液(每3个月一次)的175mg、263mg、350mg和525mg特定产品的生物等效性指导原则)
2024-07-26
-
concept paper for the development of a guideline on the demonstration of therapeutic equivalence for nasal products(概念文件针对鼻用产品治疗等效性证明的指导原则)
2024-07-26
-
chemistry of active substances (chemistry of new active substances) - scientific guideline(新药研发过程中涉及的活性物质(特别是新活性物质)化学部分-科学指南)
2024-07-25
-
development and manufacture of oligonucleotides - scientific guideline(寡核苷酸的开发与制造-科学指南)
2024-07-22
《互联网药品信息服务资格证》 证书号：（浙）-经营性-2021-0028
ICP备案号：蜀ICP备2021004927号-4
浙公网安备33011002015279
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科
品牌升级，感恩回馈
摩熵医药（个人版），邀请好友，赚取摩熵币，赢取价值1500元京东E卡
立即参与活动
邀请好友
获1500元京东卡
获1500元京东卡